An Easy-to-Use Blue Brush

May Save Your Life

BrochurePrint the InSure® FIT™ Patient Education Pamplet to bring to your physician and Request The Test.

 

 

Take the Blue Brush Challenge!

Each year, approximately 150,000 people are diagnosed with colorectal cancer - but the early indicators of this deadly disease can be found before it's too late. Colorectal cancer is largely treatable when caught at this early stage, but sadly, due to low screening rates, fewer than 40 percent of cases are caught early.

 

 

InSure FIT Patient Instructions
InSure® FIT™
Patient Instructions

(en español)

 

Download Adobe Reader

 

 

 

About the InSure® FIT™ Test

The InSure® FIT™ test and its unique Blue Brush Method make it easier to screen for colorectal cancer.

Clinical studies have shown that the InSure® FIT™ test is highly sensitive for detecting blood in and around the stool, a key indicator of abnormalities in the colon and rectum that doctors use to help screen for colorectal cancer. 

The InSure® FIT™ test has an 87% sensitivity for colorectal cancer.1,2 In a study of patients who were at average risk, high risk or had no symptoms at all, InSure® FIT™ was found to have 33% greater sensitivity for colorectal cancer than a leading guaiac-based FOBT screening test.2

InSure® FIT™ Test Makes Annual Screening Easier

The InSure® FIT™ test kit provides a more convenient sample collection method, making annual colorectal cancer screening easier to fit into your life.  Doctors often say that the best test is the one that is completed.


Here’s why:

The InSure® FIT™ test is available from your doctor. The Patient Collection Kit contains everything you need to collect and submit test samples for analysis.

 

It's Time to Challenge Colon Cancer. DO YOU HAVE THE GUTS?

 


  1. InSure® FIT™  product inserts
  2. Smith A, Young GP, Cole SR, et al. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer. 2006;107:2152-2159.  The study was funded in part by Enterix Inc. (through Enterix Australia Pty. Ltd), the manufacturer of InSure® FIT™.  One of the authors, GP Young, is a consultant for Enterix Australia Pty. Ltd.
  3. Cole SR, Young GP, Esterman A, Cadd A, Morcom J. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen 2003;10:117-122.